Dr Richard Angell
Head of Drug Discovery Group
Richard started his career with Glaxo in 1992 working on respiratory, inflammation and oncology projects. In 2001, Richard joined Arrow Therapeutics, a UCL spinout company, a chemistry section head leading several novel antibacterial drug discovery programmes.
In 2007, following the acquisition of Arrow Therapeutics by AstraZeneca, Richard was Head of Discovery leading a multi-disciplinary team focusing on early stage antiviral drug discovery projects.
Richard joined the Translational Research Office in November 2012, to set up the Drug Discovery Group at the UCL School of Pharmacy.